The company expects to receive approval from the U.S. drug regulators for a treatment for atopic dermatitis—or eczema—by the ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD).

The brand benefits from the growing demand for science-based skincare products. In therapeutic dermatology (19% of 2023 net sales), Galderma is a market leader in acne, rosacea, and actinic keratosis.

The European Medicines Agency’s human medicines committee has recommended Galderma’s nemolizumab to treat atopic dermatitis ...

Swiss skincare company Galderma is banking on a dermatological drug to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.

Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing ...

Switzerland’s Galderma has won US Food and Drug Administration (FDA) approval for the use of Nemluvio (nemolizumab) for ...